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Kinase insert domain receptor/vascular
endothelial growth factor receptor 2 (KDR)
genetic variation is associated with ovarian
hyperstimulation syndrome
Travis J O’Brien1*, Arthur F Harralson1,2, Tuyen Tran3, Ian Gindoff1, Funda E Orkunoglu-Suer4, David Frankfurter5
and Paul Gindoff5

Abstract
Background: The objective of this investigation was to determine if kinase insert domain/vascular endothelial
growth factor receptor 2 (KDR/VEGFR2) genetic variation was associated with the development of ovarian
hyperstimulation syndrome (OHSS) in patients undergoing controlled ovarian hyperstimulation (COH).
Methods: This was a case–control study of 174 patients who underwent controlled ovarian stimulation. Patient
blood samples were genotyped for single nucleotide polymorphisms (SNPs) spanning the KDR locus. OHSS
development, clinical outcome variables, SNP and haplotype frequencies were compared between control (n = 155)
and OHSS (n = 19) groups.
Results: Patients who developed OHSS had significantly higher response markers (estradiol levels of the day of hCG
administration, number of follicles developed, number of eggs retrieved) than control patients. When adjusted for
age and self-identified race, the rs2305945 G/T genotype was associated (P = 0.027) with a decreased risk (OR = 0.30;
95% CI = 0.10, 0.93) of developing OHSS using an overdominant model. The rs2305945 G/T variant was also
associated with decreased COH response (number of follicles, number of eggs retrieved) in an overdominant model.
The rs2305948, rs1870378, rs2305945 (C-T-G) haplotype was associated with both decreased COH response and
OHSS risk (unadjusted OR = 0.10; 95% CI = 0.01, 0.80, P = 0.031).
Conclusions: The KDR receptor is believed to play a central role OHSS development and is a target for
pharmacological prevention of OHSS. These results indicate that genetic variation in the KDR gene may impact
individual risk of developing OHSS from COH. In addition, the rs2305948 SNP and C-T-G haplotype might serve
as potential biomarkers for poor ovarian response to COH.
Keywords: Ovarian stimulation, Ovarian hyperstimulation syndrome, OHSS, KDR, VEGFR2, Polymorphism

Background
Controlled ovarian hyperstimulation (COH) has played
a leading role in improving outcomes from in vitro
fertilization (IVF). The backbone of COH pharmacotherapy
involves the use of exogenous gonadotropins. While there
are several clinical predictors [1-4] of ovarian responsiveness that aid in individualizing COH [5,6], interindividual
* Correspondence: phmtjo@gwu.edu
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Full list of author information is available at the end of the article

variation in response to gonadotropin administration still
exists. Additionally, patient risk of developing complications from COH is similarly unpredictable.
For the normal responder, COH is associated with some
degree of risk for the iatrogenic complication ovarian hyperstimulation syndrome (OHSS). Potentially life threatening, OHSS leads to hospitalization in 1.9% of IVF cases
[7]. Moderate to severe OHSS may be underestimated
since many such cycles are frequently cancelled or result
in the cryopreservation of all embryos [8]. Mild OHSS is
relatively common with symptoms including abdominal
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bloating and mild weight gain. OHSS is characterized by
cystic enlargement of the ovaries, increased vascular permeability (VP) and movement of fluid from the peritoneal
vasculature into the third space. Symptoms and signs of
severe OHSS include dyspnea, hemoconcentration, diminished renal perfusion and thromboembolism [9,10]. In
cases of severe OHSS, myocardial infarction and/or stroke
can lead to death [9,10]. Early onset OHSS occurs within
3–5 days after oocyte retrieval and is related to the hyperresponse of the ovaries to COH followed by the use of
hCG for oocyte maturation. Late onset OHSS appears 9–
12 days after oocyte retrieval and results from COH and
the endogenous hCG produced by a developing embryo
[11]. Although rare, spontaneous cases of OHSS have been
reported with the supra-physiologic hCG levels seen with
multiple gestations or molar pregnancy [12]. Reports of familial spontaneous gestational OHSS suggest a genetic
cause [13]. Regardless of severity, the development of
OHSS is associated with significant physical, psychological
and financial implications [14].
Standard practice emphasizes an avoidance approach in
preventing OHSS (see below). There are several known
risk factors for OHSS development that can assist in tailoring gonadotropin dosage [15-17]. In addition, markers
for COH response (i.e. baseline anti-mullerian hormone
(AMH) levels, estradiol levels, intermediate follicle number and FSH levels) may serve as early indicators allowing
corrective measures to be taken to decrease severity of
OHSS. Specific preventative strategies include coasting,
avoiding the use of hCG, delaying/reducing hCG administration or cryopreserving all embryos [18]. Unfortunately, beyond avoiding hCG for oocyte maturation, most
current, proactive measures are not completely effective in
preventing OHSS.
The molecular etiology of OHSS is unclear. Elevated
serum estradiol [14], cytokine and interleukin levels have
all been detected in the peritoneal fluid of women with
OHSS [19,20]. Moreover, roles for renin-angiotensin,
prolactin and prostaglandins in the increased VP observed during OHSS have also been proposed [21]. The
most important VP factor in the ovaries is vascular
endothelial growth factor (VEGF). In rats, VEGF mRNA
levels and VP increased following gonadotropin stimulation [22] which was reversed by VEGF antiserum [23].
In humans, hCG administration increased VEGF expression in granulosa-lutein cells [24] and VEGF blood levels
predicted the development of OHSS and its severity
[25]. In addition, a single nucleotide polymorphism in
the VEGF gene has been associated with increased
OHSS risk [26]. Consequently, the prevailing model for
OHSS development involves aberrant VEGF signaling as
a key factor driving increased VP [23,27].
In the ovaries, VEGF-mediated VP, at least in part, is
mediated by the kinase insert domain/vascular endothelial
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growth factor receptor 2 (KDR/VEGFR-2/Flk-1) signaling
mechanisms [28-33]. In support of this, inhibition of both
VEGF [34,35] and KDR [22,31,32,35] has been shown
to ameliorate VP development in models of OHSS. In
addition, dopamine [36] and [37] dopamine receptor agonists [20,27,38-40] are known inhibit KDR function
[36,41] and show promise as both preventative and therapeutic options for OHSS [39,42-45].
Despite much research on the topic, very few predictive genetic biomarkers exist for COH outcome [46].
Genetic variation in FSHR [47], CYP19A1 [47], BMP15
[48], VEGF [26] and LHCGR [49] have all been associated with high response to COH and/or OHSS. KDR has
been implicated in the etiology of OHSS and also serves
as a target for pharmacotherapy [20,38,40,45,50]. However, no information is available on the association of
KDR genetic variability and OHSS risk. As a result, the
focus of this investigation was to evaluate the role of
KDR polymorphisms in the development of OHSS.

Methods
This study was approved by George Washington University Institutional Review Board. Patients’ and written informed consent was obtained prior to enrollment of
patients (2010–2011). All IVF patients (>18 years of age)
who were treated at the GW Fertility and IVF Center
with injectable gonadotropins were invited to participate.
All patients were evaluated for ovarian reserve testing,
semen analysis (male partner), uterine cavity study and
thyroid screening. Controlled ovarian stimulation protocols were as previously described [49]. After initial follicular monitoring (serum estradiol and transvaginal
ultrasound assessments), FSH dosing was titrated based
upon the ovarian response. hCG trigger was withheld for
E2 levels over 4000 pg/ml thus minimizing risk for
OHSS. Both control and OHSS groups had similar risk
factors including those identified at time of hCG trigger.
Ovarian hyperstimulation syndrome was defined clinically
based on established criteria [51,52]. For each patient the
following clinical endpoints were recorded: estradiol level
on day of hCG injection, number of ovarian follicles on
day of hCG, number of follicles/follicles >16 mm), number
of eggs retrieved and the incidence of OHSS.
For each patient, blood (5 mL) was collected and DNA
was extracted using a QiaCube automated instrument with
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA).
KDR/VEGFR-2 SNPs rs3025035, rs2305948, rs2219471,
rs1870378, rs2305945 and rs1870377 were genotyped
using Real-Time PCR (TaqMan®). PCR was performed
with a reaction volume of 10 μl, including 4.75 μl of
TaqMan® Universal PCR Master Mix, 0.5 μl of 20X
DME Genotyping Assay Mix, 3.75 μl of DEPC H2O, and
1.0 μl of genomic DNA. The PCR cycling conditions
were as follows: 1 cycle of 50°C for 2 minutes, followed
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by 1 cycle of 95°C for 10 minutes and 50 cycles of 92°C
for 15 seconds and 60°C for 90 seconds. Appropriate
negative controls were included with each run. Allelic
discrimination was carried out by measuring fluorescence intensity using an ABI 7300 Real Time PCR System (Applied Biosystems) and SDS software Version 1.3
(Applied Biosystems). PCR/sequencing primers are
shown in Table 1. The genotype calls for each SNP were
verified in subsets of samples by DNA sequencing as
previously described [49] using PCR primers in Table 1.
Comparisons between OHSS and control samples for
each of the clinical variables were conducted using SPSS
(IBM, Armonk, NY). Due to the skewed nature of the data
an independent samples Mann–Whitney U test was used
for all comparisons. SNPs spanning the KDR locus were
selected using Haploview (version 4.2, r2 > 0.75) [53] (CEU
population) [54]. Analyses for Hardy-Weinberg equilibrium, linkage disequilibrium (LD) and unadjusted odds ratios for OHSS risk were conducted using SNPSTATS [55]
and HAPSTAT [56].

Results
We obtained genotypic and clinical information for 174
patients who underwent IVF. We have previously reported
on the association of LHCGR rs4073366 C allele carrier
status with OHSS (n = 172) risk in this patient population
[49]. However, we did not perform statistical comparisons
of the control and OHSS populations’ clinical characteristics. OHSS patients (n = 19) had significantly greater COH
response markers than control patients (n = 155). Specifically, estradiol (E2) levels (median; 25%, 75% percentile) on
the day of hCG administration [Controls: 1735.0 pg/mL
(1031.0-2280.0); OHSS: 2606.0 pg/mL (1996.0-3471.0)],
number of follicles (median; 25%, 75% percentile) generated [Controls: 2.0 (1.0-4.0); OHSS: 5.0 (3.0-10.0)] and
number of eggs (median; 25%, 75% percentile) retrieved
[Controls: 8.0 (4.0-13.0); OHSS: 18.0 (13.0-26.0)] were
all significantly (P < 0.001) higher in OHSS patients. In
addition, OHSS occurred to a greater extent in patients
of self-identified Caucasian ethnicity versus Black, nonHispanic or Asian/Pacific Islander [49].
Six SNPs in the KDR gene were investigated for association with OHSS. SNPs were selected based on pairwise linkage disequilibrium analysis using HapMap [57]
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data (CEU population) in the KDR for the prediction of
haplotype blocks. The 6 SNPs (rs3025035, rs2305948,
rs2219471, rs1870378, rs2305945, rs1870377) spanning
the KDR gene were selected and genotyped in both control and OHSS patients. SNPs that were not in Hardy
Weinberg equilibrium (rs3025035, rs2219471, rs1870377)
were omitted from further analysis. The remaining SNPs
rs2305948, rs1870378 and rs2305945 were not in linkage
disequilibrium (See Additional file 1: Table S1) and existed
in 3 separate predicted haplotype blocks (data not shown).
Specifically, tagged SNPs rs1870378 and rs2305945 included rs2219471 and rs6838752 (covering ~5 kb) and
rs3828550 and rs13109660 (covering ~5 kb), respectively.
For rs2305948, C/C, C/T and T/T variants occurred at
frequencies of 0.75, 0.23 and 0.02, respectively in the entire patient population (Table 2). The observed frequencies for rs1870378 C/C, C/T and T/T genotypes were
0.55, 0.37 and 0.07 of all patients in the study. The
rs2305945 G/G, G/T and T/T variants were found at frequencies of 0.40, 0.45 and 0.14 in the total population as
well. Although there were differences in the frequencies
of SNPs in OHSS case versus control patients, none
reached statistical significance (alpha of 0.05).
None of the individual SNPs were independent predictors (unadjusted) of OHSS risk (data not shown). In an
overdominant model, rs23205945 was associated (P =
0.031) with decreased OHSS risk (OR = 0.30; 95% CI =
0.10, 0.93) when corrected for age and self-identified race
(Table 3). When adjusted for age (P = 0.017), race (P =
0.017) or both age and race (P = 0.013), the rs2305945 G/T
genotype was significantly associated with fewer follicles
generated by COH (See Additional file 2: Table S2). In
addition, the rs2305945 G/T genotype was marginally associated (P = 0.046) with a fewer number of eggs retrieved
in an overdominant model only after adjustment for selfidentified race (See Additional file 3: Table S3).
A significant difference in haplotype distribution between
OHSS cases and control patients (P = 0.033) was observed.
Interestingly, one (rs2305948, rs1870378, rs2305945; T-TT) of the eight possible haplotypes was not observed in either the OHSS case or control populations (Table 4). Two
haplotypes (T-C-G, T-C-T) were not detected in the OHSS
population, but also occurred at low frequencies (<5.0%) in
the control population as well. All missing haplotypes were

Table 1 Primer sequences for DNA sequencing
SNP

Forward (5′ to 3′)

Reverse (5′ to 3′)

rs2219471

TCCACAGGGATTGCTCCAAC

ATATTTGGCCCCGTGGAGTG

rs3025035

CAGGGGTCCTTGGGAAAGAT

AGAACAGGCCCTACCCTTCT

rs2305945

GTGGGTACTAAGCTATGTAATTCCC

CCACACAGAGCTTGTGGTTTA

rs2305948

TTTCCAAGACCATAGCTTACCAT

CAGCATCAGCATAAGAAACTTGTA

rs1870377

TGGTACTGCTAAAAGTCAATGG

GGCTGCGTTGGAAGTTATTT

rs1870378

CACTACGGCCTCAAGAGAGAAG

CTGGGTTCCCAAATGTTATGCG
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Table 2 SNP frequencies in controls and OHSS cases
Variant
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Table 4 Haplotype estimation (n = 174)

Frequency
Total (n = 174)

Controls (n - 155)

Haplotype
OHSS Cases (n = 19)

rs2305948

Frequency

rs2305948

rs1870378

rs2305945

Total

Control

OHSS Cases

C

C

G

0.352

0.334

0.474

CC

131 (0.75)

116 (0.75)

15 (0.79)

C

C

T

0.327

0.329

0.342

CT

40 (0.23)

36 (0.23)

4 (0.21)

C

T

G

0.164

0.185

0.026

TT

3 (0.02)

3 (0.02)

0

T

T

G

0.073

0.069

0.105

T

C

G

0.041

0.044

–

rs1870378
CC

96 (0.55)

83 (0.54)

13 (0.68)

C

T

T

0.025

0.017

0.053

CT

65 (0.37)

60 (0.39)

5 (0.26)

T

C

T

0.019

0.022

–

TT

13 (0.07)

12 (0.08)

1 (0.05)

T

T

T

–

–

–

GG

70 (0.40)

61 (0.39)

9 (0.47)

GT

79 (0.45)

74 (0.48)

5 (0.26)

TT

25 (0.14)

20 (0.13)

5 (0.26)

rs2305945

not included in the haplotype-based logistic regression
analysis. The rs2305948, rs1870378, rs2305945 (C-T-G)
haplotype (unadjusted) was found to be moderately protective (P = 0.031) for OHSS risk (OR = 0.10; 95% CI =
0.01, 0.80) (Table 5). When adjusted for age (P = 0.020),
race (P = 0.023) or age/race (P = 0.011), the C-T-G haplotype was significantly associated with decreased OHSS development (Table 6). Additionally, COH response variables
number of follicles >16 mm and eggs retrieved were
significantly lower in the C-T-G haplotype (See Additional
file 4: Table S4 and Additional file 5: Table S5). Only one
other haplotype (C-C-T) was significantly associated
with an endpoint (fewer follicles > 16 mm) (See Additional
file 6: Table S6).

Discussion
The aim of this investigation was to determine whether
KDR genetic variation was associated with OHSS risk in
COH patients. We found a novel association between
the KDR rs2305948, rs1870378, rs2305945 C-T-G haplotype and reduced risk of developing OHSS. Patients with

this haplotype also exhibited decreased ovarian response
to COH (i.e. number of follicles >16 mm, eggs retrieved).
In addition, the rs2305945 G/T variant was similarly associated with decreased response to COH and lower risk
of hyperstimulation. These findings are the first to suggest that KDR polymorphisms might serve as predictive
genetic biomarkers for ovarian response to COH.
A central component of the pathophysiology of iatrogenic OHSS is increased ovarian VP during COH. The
molecular mechanism for increased VP is thought to involve aberrant VEGF signaling [58]. Serum VEGF levels
are elevated in OHSS and predictive for OHSS risk [59].
In addition, a VEGFA polymorphism has been as recently
identified as a risk allele for OHSS [26]. VEGF-mediated
VP is thought to act through KDR-dependent mechanisms
and dopamine/dopamine receptor agonists [27,36], which
purportedly inhibit KDR function, have shown promise as
therapies for OHSS [27,39,42-44]. Interestingly, we observed a moderate association between the (rs2305948/
rs1870378/rs2305945) C-T-G haplotype and lower OHSS
risk. Given that the pathophysiology of OHSS involves increased VP, these results suggest that C-T-G haplotype
could potentially result in a KDR receptor with decreased
function.
The C-T-G haplotype included two intronic SNPs:
rs1870378 (in intron 15) and rs2305945 (intron 12). Neither

Table 3 rs2305945 association with OHSS (n = 174, Adjusted for Age and Race)
Model

Genotype

Controls

OHSS

OR (95% CI)

P-value

Codominant

G/G

61 (39.4%)

9 (47.4%)

1

0.064

G/T

74 (47.7%)

5 (26.3%)

0.35 (0.10, 1.19)

T/T

20 (12.9%)

5 (26.3%)

1.70 (0.46, 6.34)

Dominant

Recessive

Overdominant

G/G

61 (39.4%)

9 (47.4%)

1

G/T-T/T

94 (60.6%)

10 (52.6%)

0.59 (0.21, 1.65)

G/G-G/T

135 (87.1%)

14 (73.7%)

1

T/T

20 (12.9%)

5 (26.3%)

2.79 (0.82, 9.47)

G/G-T/T

81 (52.3%)

14 (73.7%)

1

G/T

74 (47.7%)

5 (26.3%)

0.30 (0.10, 0.93)

0.320

0.110

0.027
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Table 5 Haplotype frequencies estimation and association with OHSS (n = 174)
Haplotype

rs2305948

rs1870378

rs2305945

OR (95% CI)

P-value

1

C

C

G

1

—

2

C

C

T

0.72 (0.32, 1.59)

0.42

3

C

T

G

0.10 (0.01, 0.80)

0.031

4

T

T

G

1.15 (0.34, 3.87)

0.82

5

T

C

G

–

–

6

C

T

T

2.72 (0.35, 21.30)

0.34

7

T

C

T

–

–

Global haplotype association p-value: 0.033.

of these polymorphisms have been associated with disease
risk or clinical outcomes. In contrast, the rs2305948 (G >
A) variant is a nonsynonymous SNP located in exon 7 that
results in an amino acid change from valine to isoleucine
(codon 297). It resides in the NH2-terminal portion of the
receptor located in the extracellular, ligand-binding domain.
In vitro evidence suggests that rs2305948 (G > A) variant
decreases KDR binding to VEGF [60]. Clinically, rs2305948
has been associated with increased risk of coronary artery
disease [60], intracerebral hemorrhage and stroke recurrence [61]. In addition, the rs2305948 T allele exists in a
haplotype with rs10020464 and rs7692791 that was moderately associated with a lower risk of developing neovascular
age-related macular degeneration [62]. However, we found
that the rs2305948 C allele in the C-T-G haplotype was associated with decreased OHSS risk. Therefore, the exact
role, if any, which the rs2305948 C allele plays in the apparent protection from OHSS provided by the C-T-G haplotype, requires further investigation.
We found only one polymorphism to be moderately associated with OHSS development when corrected for covariates (age, race) known to be independent predictors of
OHSS risk [8,49]. The rs2305945 G/T genotype was associated with a reduced likelihood of OHSS (OR = 0.30;
95% CI = 0.10, 0.93) in an overdominant model. This SNP
resides within intron 12 located ~153 bp downstream of
exon 12. It is intriguing that the rs2305945 genotype and
the C-T-G haplotype were associated with both decreased
ovarian response and lower risk of OHSS. We postulate
Table 6 Haplotype (CTG) association with OHSS risk
Haplotype

OR

95% CI

P-value

0.10

0.01, 0.80

0.031

Age

0.08

0.01, 0.66

0.020

Race

0.08

0.01, 0.69

0.023

Age, Race

0.04

0.00, 0.46

0.011

rs2305948 (C), rs1870378 (T), rs2305945 (G)
Unadjusted

Adjusted

that rs2305945 SNP could impact KDR mRNA processing
and/or stability leading to decreased downstream signaling. However, the precise mechanism by which the G/T
heterozygote impacts KDR function requires additional
mechanistic studies.
The majority of poor responders to COH suffer from reduced ovarian reserve [63]. While this study has identified
potential protective genetic biomarkers for OHSS, the results are also potentially applicable to identifying patients
with diminished ovarian reserve (DOR). To date, there are
very few genetic biomarkers for DOR [64-67]. We found
that the rs2305945 SNP and the C-T-G haplotype were
both associated with diminished ovarian response to
COH. It would be interesting to specifically investigate the
frequency of these variants in COH poor responders and/
or patients with DOR. As a result, our results offer promise that KDR polymorphisms might also serve as novel,
predictive biomarkers for DOR in COH patients.
The KDR receptor plays an integral role in ovarian VP
and has shown promise as a target for pharmacologic
intervention to prevent OHSS. However, there is no
information available on the impact of KDR polymorphisms on patient risk of developing OHSS during
COH. The results from this preliminary study indicate
that KDR polymorphisms are potential predictive biomarkers for OHSS development. We believe this is the
first study to link KDR polymorphisms with OHSS risk
and decreased ovarian response to COH. A limitation of
the study was the small number of OHSS cases available
for analysis. The significance of these findings requires
validation in a larger, separate population of patients.
Given that the variants identified in this study have individually small effect sizes, future work is aimed at
uncovering other risk alleles in KDR and other genes implicated in ovarian angiogenesis and VP.

Conclusions
The KDR receptor plays a central role in VEGFmediated vascular permeability in OHSS and represents
a potential target for pharmacologic intervention of
OHSS. These results indicate that genetic variation in
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the KDR gene may impact individual risk for developing
OHSS from COH. In addition, these results suggest that
the rs2305948 variant and C-T-G haplotype may serve as
potential biomarkers for diminished response to COH.
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Additional file 2: Table S2. rs2305945 association with number of
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Additional file 3: Table S3. rs2305945 association with number of eggs
retrieved (n = 174).
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